Johnson & Johnson's drug improved mania symptoms by Day 3 in a second study.
Johnson & Johnson's drug improved mania symptoms by Day 3 in a second study. Stock Titan
Covered in this story
Analyst targets on Johnson & Johnson
- Bernstein: at $253 · target $270 by Oct 2027 · Market Perform via Investing.com
- RBC Capital Markets: at $249 · target $280 by Oct 2027 · Outperform via GuruFocus
- RBC Capital Markets: at $255 · target $290 by Oct 2027 · Outperform via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 36 stories mentioning Johnson & Johnson, the earliest published 28 Apr 2017.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.